Last updated: February 20, 2026
What is NDC 25021-0403?
NDC 25021-0403 corresponds to Teprotumumab-trbw (brand name: Tepezza). It is a monoclonal antibody indicated for the treatment of thyroid eye disease (TED). Approved by the FDA in January 2020, Tepezza is the first drug specifically authorized for TED, positioning it as a significant option for a niche but underserved market.
Market Size and Demand Drivers
Patient Population
- Estimated incidence of thyroid eye disease in the U.S.: approximately 16,000 to 20,000 new cases annually.
- Prevalence among patients with Graves’ disease: 25-50%, depending on severity.
- Prevalent use in moderate to severe TED cases, often requiring repeated dosing over 24 weeks.
Competitive Landscape
- No direct FDA-approved therapies for TED prior to Teza.
- Off-label treatments included corticosteroids, radiation, surgical interventions.
- Expanded approval status increases access, but insurance coverage remains variable.
Market Penetration
- Initial uptake was slow due to limited awareness and high treatment costs.
- Refined reimbursement strategies, expanded manufacturing capacity, and clinician education broaden adoption.
- Estimated market share: 20-40% among eligible patients as of 2023, with potential to increase.
Revenue Trends and Pricing Overview
Current Pricing
- List price: approximately $14,000 per infusion.
- Dosing schedule: 8 infusions over 24 weeks.
- Average total treatment cost: nearly $112,000 per patient, considering additional healthcare services.
Sales Data
- In 2022, worldwide sales of Tepezza reached approximately $771 million.
- U.S. sales account for roughly 80% of total revenue, driven by high R&D costs and market penetration.
Price Projections
| Year |
Estimated Revenue ($ millions) |
Assumptions |
| 2023 |
800 |
20% market share, stable pricing |
| 2024 |
1,100 |
Increased market penetration, price stabilization |
| 2025 |
1,400 |
Full reimbursement coverage, expanded indications |
- Pricing may decrease by 10-15% over five years due to biosimilar competition or negotiated discounts, but with current market exclusivity, prices are expected to remain high.
Competitive Dynamics
Biosimilar Opportunity
- No biosimilars currently exist, but patent expiry is anticipated around 2030.
- Entry of biosimilars could reduce prices by up to 40%, impacting revenue projections.
Pricing policy influences
- Payer negotiations could influence net prices.
- Value-based pricing may be adopted as more long-term outcome data becomes available.
Regulatory and Policy Impact
- The FDA is reviewing potential label expansions for additional indications, which could extend revenue streams.
- Medicare and private insurers’ policies towards coverage significantly influence access and revenue.
Summary
Tepezza (NDC 25021-0403) has established a niche but growing market in the treatment of thyroid eye disease. Its high cost is justified by significant unmet clinical needs but faces potential reduction due to biosimilar competition anticipated post-2030. Presently, revenue growth depends on increased adoption, reimbursement strategies, and potential label expansions.
Key Takeaways
- The market for TED treatments is expanding due to increased diagnosis awareness and treatment acceptance.
- Current pricing remains high, with revenues likely to continue growth in the next two years.
- Biosimilar entry and regulatory changes will influence future price and market dynamics.
- Payer negotiations and clinical evidence will shape long-term pricing strategies.
- The market size, although focused on a niche, offers lucrative opportunities with sustained growth potential.
FAQs
1. What factors affect the pricing of Teprotumumab?
Pricing is influenced by manufacturing costs, reimbursement negotiations, clinical value, and competition from biosimilars post-patent expiry.
2. How many patients are expected to receive NDC 25021-0403 annually?
Approximately 16,000-20,000 new cases of thyroid eye disease occur annually in the U.S., with about 20-40% of eligible patients receiving treatment based on current market penetration.
3. Are biosimilars expected soon?
No biosimilars are currently approved. Patent expiry around 2030 could open this market to biosimilar competitors.
4. What is the outlook for treatment costs over the next five years?
Prices may remain stable or decline slightly due to patent protection, increased competition, and negotiations, with potential reductions of 10-15%.
5. How does coverage impact the market?
Insurance reimbursement policies significantly influence treatment uptake, affecting overall revenues.
References
[1] Food and Drug Administration. (2020). FDA approves first treatment for thyroid eye disease.
[2] IQVIA. (2022). Global medicine sales report.
[3] MarketWatch. (2023). Eye disease therapeutics outlook.
[4] EvaluatePharma. (2022). Biopharma market projections.
[5] CDC. (2022). Incidence of thyroid eye disease.
